Article | August 18, 2021

Building An Army: Cell Therapy Platforms With Dr. Helen Sabzevari, CEO Of Precigen

Source: Cytiva

By Cytiva

iStock-1221576332-cell

Two of the greatest challenges in cell therapy development and driving new therapies toward commercial success are scalability and optimizing cost.

As the CEO of Precigen, a biopharmaceutical company dedicated to pursuing solutions for a range of intractable diseases through early discovery and clinical-stage research, Dr. Helen Sabzevari is ready to face these challenges. Dr. Sabzevari has spent years considering what it takes for rapid drug development and commercial viability in today’s market. Her previous work includes tenures in both academia and with EMD Serono, Compass Therapeutics, and Intrexon (now Precigen).

In a recent episode of The Business of Biotech, Dr. Sabzevari discussed how Precigen has used customized therapeutic and platform technologies to tackle scale-up in the CAR-T therapeutics space, helping patients and investors know they’re getting the most effective therapy at the best price.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: